Latest news for Glomac (OTC:GLOCF) Stock

Glomac Bhd is a real estate development company. It is engaged in property development, construction of buildings, and property investment. The firm is organized into three areas of business. The Property development segment includes the development of residential land and commercial properties for sale and sale of land; Construction includes the construction of buildings, and Property investment includes the investment of land and buildings held for investment potential and rental income in the future. It derives the majority of its revenues from the property development segment. The group geographically operates and derives its income in Malaysia.

Glomac Bhd

Cantor Fitzgerald analyst Josh Schimmer reiterates ARS Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRY#NASDAQ">SPRY</a>) with a Overweight and maintains $30 price target.

News

Price Target

Reiteration

Analyst Ratings

SPRY

Cantor Fitzgerald Reiterates Overweight on ARS Pharmaceuticals, Maintains $30 Price Target

WIIM

Mattel shares are trading higher amid the company's presentation at the Communacopia and Technology Conference.

Mattel, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>) today announced that Ynon Kreiz, Mattel's Chairman and Chief Executive Officer, and Anthony DiSilvestro, Mattel's Chief Financial Officer, will participate in a fireside chat at the Goldman Sachs Communacopia and Technology Conference on Monday, September 9, 2024 at 11:50 a.m. Eastern time.
The webcast will be available on Mattel's Investor Relations website, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.mattel.com%2F&amp;esheet=54114193&amp;newsitemid=20240827287460&amp;lan=en-US&amp;anchor=https%3A%2F%2Finvestors.mattel.com%2F&amp;index=1&amp;md5=909add11d02dd281ae467dea7b913f61">https://investors.mattel.com/</a>. To listen to the webcast, log onto the website at least 15 minutes early to register, download, and install any necessary software. An archive of the webcast will be available on the Company's website shortly after the completion of the live webcast.

Events

Trading Ideas

Watching Mattel; Shares See Volume To The Upside, Co Currently Presenting At The Goldman Sachs Communacopia and Technology Conference

Parsons Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSN#NYSE">PSN</a>) shares are trading higher on Monday after the company won a three-year contract worth $68.5 million <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g40769132/parsons-supports-u-s-indo-pacific-defense-with-68-5-million-u-s-army-infrastructure-contract" rel="noreferrer noopener">from the U.S. Army Corps of Engineers (USACE) Honolulu District.</a>
As per the contract, Parsons will build new army housing units on-island, its second such contract in under a year.
The contract involves the design-bid-build delivery of new U.S. Army housing units in the Kwajalein Atoll, Republic of the Marshall Islands, marking new work for the company.
Parsons was also chosen by the USACE Honolulu District for its Pre-Qualified Source Listing (PQSL), which qualifies the company to receive future large task orders valued at $50 million or more within the district&#8217;s jurisdiction.
In October 2023, the company also secured a $44 million contract for army housing as part of the Department of the Army&#8217;s modernization efforts.
Jon Moretta, President, Engineered Systems for Parsons, said, &#8220;This award expands our work in the Kwajalein Atoll, a uniquely complex environment for infrastructure due to the logistical challenges of servicing the remote location as well as the highly corrosive and humid environment.&#8221;
Last month, Parsons was selected as the lead engineer for the $4.6 billion State Route 400 Express Lanes Major Mobility Investment Program by the Georgia Department of Transportation and the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/g40571266/parsons-selected-as-lead-engineer-to-add-express-toll-lanes-to-state-route-400-in-georgia" rel="noreferrer noopener">Georgia State Road and Tollway Authority</a>.
Investors can gain exposure to the stock via&nbsp;Global X Funds Global X Defense Tech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHLD#NYSE">SHLD</a>) and&nbsp;Professionally Managed Portfolios Otter Creek Focus Strategy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OCFS#NYSE">OCFS</a>).
Price Action: PSN Shares are up 5.54% at $96.98 at the last check Monday.
Image via Shutterstock
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Large Cap

Contracts

Movers

Professionally Managed Portfolios Otter Creek Focus Strategy ETF

OCFS

SHLD

Parsons Shares Soar On Grabbing $68.5M Army Housing Contract

SINTX Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares surged 91.5% to $5.40 Monday after receiving a Notice of Allowance from the U.S. Patent and Trademark Office for its <a href="https://www.benzinga.com/pressreleases/24/09/g40770854/sintx-receives-notice-of-allowance-for-united-states-patent-application-for-silicon-nitride-functi">patent</a> on zirconia-toughened alumina surface functionalization methods.
The patent covers methods for bonding bioactive silicon nitride, or a mixture of silicon nitride and bioactive glass, to zirconia-toughened alumina (ZTA) surfaces. 
The aim of this technology is to integrate silicon nitride's properties, such as enhanced osseointegration and bacterial resistance, into the typically inert ZTA substrates, which are used in medical device manufacturing.
Eric K. Olson, President and CEO of SINTX, stated that the patent allowance represents progress in the company&#8217;s intellectual property portfolio and supports its efforts to develop new biomaterials for medical applications.
SINTX says the company is currently the only FDA-registered producer of implantable silicon nitride and has recently introduced a particulate form of the material that can be used in composites and coatings.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40773576/us-yield-curve-no-longer-inverted-why-this-time-the-recession-scenario-might-be-d">US Yield Curve No Longer Inverted: Why This Time The Recession Scenario Might Be Different For Investors</a>
<h2 class="wp-block-heading">How To Buy SINT Stock</h2>
By now you're likely curious about how to participate in the market for SINTX Techs &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. 
In the the case of SINTX Techs, which is trading at $5.95 as of publishing time, $100 would buy you 16.81 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, SINT has a 52-week high of $212.00 and a 52-week low of $2.75.

SINT

Why SINTX Technologies Stock Is Up 100% Today

The&nbsp;PNC Financial Services Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNC#NYSE">PNC</a>) announced today that Chairman and Chief Executive Officer William S. Demchak and Executive Vice President and Chief Financial Officer Robert Q. Reilly will discuss business performance and strategy at 12:00 p.m. (ET) Monday, Sept. 9, at the Barclays Global Financial Services Conference in New York City.
The following will be accessible at <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4240242-1&amp;h=2515064954&amp;u=http%3A%2F%2Fwww.pnc.com%2Finvestorevents&amp;a=www.pnc.com%2Finvestorevents">www.pnc.com/investorevents</a>: a link to the live webcast; related materials, including cautionary statements regarding forward-looking information, available prior to the start of the webcast; webcast replay available for 30 days.

Watching PNC Financial Services Group; Shares See Volume To The Upside, Co Currently Presenting At The Barclays Global Financial Services Conference

Cantor Fitzgerald analyst Eric Schmidt reiterates Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Overweight and maintains $96 price target.

Cantor Fitzgerald Reiterates Overweight on Avidity Biosciences, Maintains $96 Price Target

81.8% ORR by BICR and 63.6% confirmed ORR by BICR at the 240 mg dose; 46.2% confirmed ORR in CNS Metastases &nbsp;
90.9% (n = 20/22) of patients with confirmed responses remained on study with a median duration of response not yet reached at time of analysis
ArriVent to host virtual webinar on these interim analyses of Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC on September 9, 2024 at 4:30 pm ET
NEWTOWN SQUARE, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced positive proof-of-concept randomized global Phase 1b FURTHER interim data for first-line firmonertinib monotherapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR PACC mutations at a Presidential Symposium Presentation at the IASCLC 2024 annual World Conference on Lung Cancer (WCLC), in San Diego, California. ArriVent plans to host a virtual webinar on September 9, 2024 at 4:30 pm ET. To register for the event, please click <a href="https://www.globenewswire.com/Tracker?data=bGFhyJRszIzvbF-7XqXvvmKpoRII_m4sAvQhEfGNfUWjUQNRbK8X2AOO9X72qUqIRGLbGpGXB-JTVmh-2q8VIaI8Mkpf6EnCRML_QyzHjCWpAjKZiN5zV-a2aV-DT0AQvH3DchCC0Lou6CIuI818V9mR4Pqtfn6Ve-eBSmc-Bo0ov7xmP298Y1H4fD8rhau7rWr01VEipjr0g8y7hxl7s6--qCUlq-OEEuMPnvDTkXplkmfOrT-HgqBgBn7bPgkug9WgLK_p42ZCKS61St45UVCNWkp78BeRvZNd3Zn53pLzmRiIbUdMC7-LBYYM2p61wjxj32KcHlU6qAN91D98_qNKqdtq2ddX59rWdwc9nrfxLDdgGa8UtHu8KegHGX9VWxB48M-QpJXUUjQ1-g-ZnO8Lgv91N9fyiNR-cTqOYpmAzUYhnNh1TU8TnN-kBJCNh9Mfgu-JXx-6cpRkm2S21IWorZjs7gyoSBmXRe5LSYZledxmaF6YtazOxGN10BpKxKWEddmUvmfxxe1EtDrOuHOQ_eCWYaRrbVBBj3YagppsDTlRI3m2MNcyEowPemEpsfWM2C89Op9_YCIp-yMjCg==">here</a>.

Biotech

General

AVBP

ArriVent Announces Proof-Of-Concept Global Phase 1b Interim Data For Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer; 81.8% ORR By BICR And 63.6% Confirmed ORR By BICR At The 240mg Dose; 46.2% Confirmed ORR In CNS Metastases

Cantor Fitzgerald analyst Olivia Brayer reiterates Regeneron Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) with a Neutral and maintains $1015 price target.

REGN

Cantor Fitzgerald Reiterates Neutral on Regeneron Pharmaceuticals, Maintains $1015 Price Target

<a href="https://cloud.google.com/blog/products/management-tools/introducing-log-scopes-in-cloud-observability/">https://cloud.google.com/blog/products/management-tools/introducing-log-scopes-in-cloud-observability/</a>
&nbsp;
Do you struggle to find the right data amidst all the data in your observability tools? This can make it hard to focus on what matters for your role.
Today, we are excited to introduce <a href="https://cloud.google.com/logging/docs/log-scope/create-and-manage">log scopes</a> for Cloud Logging – a major advancement in how you manage and analyze your organization's logs. Log scopes are a named collection of logs of interest within the same or different projects. They are made up of groups of <a href="https://cloud.google.com/logging/docs/routing/overview#log-views">log views</a> that control and grant permissions to a subset of logs in a <a href="https://cloud.google.com/logging/docs/routing/overview#buckets">log bucket</a>.
For example, imagine your organization has two log buckets: log bucket A with log views X, Y, and Z; and log bucket B with log views M and N. You can now create a log scope Q that encompasses log views X and Y from log bucket A and log view M from log bucket B.&nbsp;
Together with <a href="https://cloud.google.com/monitoring/settings">metrics scopes</a>, log scopes let you define a set of correlated telemetry for your application which in turn can then be used for faster troubleshooting or referencing for insights.

GOOG

GOOGL

"Google Cloud 'Cut Through The Noise With New Log Scopes For Cloud Observability'" - Blog Post

The availability of Micro-Neighborhood&#xAE; Targeting on the Company's Dynamic Audience Activation Platform meets the demand of life sciences marketers by synchronizing consumer and physician marketing &nbsp;
OptimizeRx presents panel session at Digital Pharma East: <a href="https://www.globenewswire.com/Tracker?data=tA8fr7L7-ld-_-9wCncWqKYet1Ol7b6SNxjLAGWIcKvwcp0dLLrBdptpiHgJWlAe_Q8GZOtO39Npqs6U7Ds-42asCziNzXfO-fs__vLwBCPody91dY1lKEo0nuzrEYllnUOzd1U4eOX2VPLo_2k0x85YUYFIZL6K6KY_EcwYW8uxn9pssdkhQUJTkltn7Zcajj3kri_UL8tlyaAH_B6WmVYt1KUPK5402HscogcxTkI=">Unlocking Opportunity through HCP+DTC Alignment in Omnichannel Oncology Marketing</a>
WALTHAM, Ma., Sept. 09, 2024 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Jfzc90X4JJ4E98QXu1l9MKC1luzvAnAn2OESeY69lDmOv_BThNL8Qdt2ESFlnsGAJYfjkxiZ7dC7IHWEGa52cdX-KVrbftwIDbKI5UCR-J8=">OptimizeRx Corp</a>. (the "Company")&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and prospective patients, today announces the leading AI-driven marketing technology for healthcare consumers, Micro-Neighborhood Targeting (MNT), offered on the Company's Dynamic Audience Activation Platform (DAAP), which now further unifies outreach to patient and provider audiences via the incorporation of brand eligibility signals to consumer marketing. This enhancement to DAAP enables pharmaceutical brands to deliver synchronized, AI-guided Direct-to-Consumer (DTC) and HCP campaigns, with the mission to improve the dialogue between patients and physicians throughout the treatment journey.

OPRX

OptimizeRx Launches Micro-Neighborhood Targeting, Offered On The Co's Dynamic Audience Activation Platform, Further Unifing Outreach To Patient And Provider Audiences Via The Incorporation Of Brand Eligibility Signals To Consumer Marketing

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Monday.
The Dow traded up 1.04% to 40,764.12 while the NASDAQ rose 1.31% to 16,908.76. The S&amp;P 500 also rose, gaining, 1.09% to 5,467.56.
Check This Out:<a href="https://www.benzinga.com/news/24/09/40770406/top-3-financials-stocks-that-could-blast-off-in-september"> Top 3 Financials Stocks That Could Blast Off In September</a>
Leading and Lagging Sectors Consumer discretionary shares surged by 1.7% on Monday.
In trading on Monday, utilities shares fell by 0.1%.
Top Headline
U.S. wholesale inventories increased by 0.2% month-over-month to $903.5 billion in July compared to a preliminary reading of a 0.3% rise, and versus a revised flat reading a month ago.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Sintx Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares shot up 100% to $5.63 after the company announced it received a Notice of Allowance from the United States Patent and Trademark Office for patent application no. 17/634,141 entitled &#8220;Methods of Surface Functionalization of Zirconia-Toughed Alumina with Silicon Nitride Ceramic.&#8221;</li>
<li>Shares of Intelligent Bio Solutions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBS#NASDAQ">INBS</a>) got a boost, surging 78% to $2.8150 after the company announced preliminary fourth-quarter revenue results of $730K and FY24 revenue of $3.11 million.</li>
<li>Relay Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLAY#NASDAQ">RLAY</a>) shares were also up, gaining 45% to $9.06 after the company reported interim data for its breast cancer treatment.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Edgio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGIO#NASDAQ">EGIO</a>) shares dropped 77% to $1.42. Edgio launched a strategic financial restructuring to facilitate sale and strengthen operations.</li>
<li>Shares of Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) were down 63% to $0.2974 after the company entered into exchange agreements to swap Series A preferred stock and warrants for Series C preferred stock, convertible at $0.45 per share.</li>
<li>AMC Networks Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMCX#NASDAQ">AMCX</a>) was down, falling 10% to $8.09. CSW Industrials Inc. (NASD: CSWI) will replace AMC Networks in the S&amp;P SmallCap 600.</li>
</ul>
Commodities In commodity news, oil traded up 0.5% to $68.01 while gold traded up 0.1% at $2,526.60.
Silver traded up 1.2% to $28.51 on Monday, while copper rose 1.2% to $4.1225.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.79%, Germany's DAX gained 0.72% and France's CAC 40 rose 0.95%. Spain's IBEX 35 Index rose 0.85%, while London's FTSE 100 rose 0.85%.
The BNP Paribas Real Estate Construction PMI in Ireland edged higher to 50.0 in August from 49.9 in July.
Asia Pacific Markets
Asian markets closed mostly lower on Monday, with Japan's Nikkei 225 falling 0.48%, Hong Kong's Hang Seng Index declining 1.42%, China's Shanghai Composite Index falling 1.06% and India's BSE Sensex gaining 0.46%.
Foreign exchange reserves in Singapore declined to SGD 501.3 billion in August compared to SGD 506.4 billion a month ago. The gauge for Japan's service sector rose to 49.0 in August versus 47.5 in the prior month, while the country' economy expanded by 2.9% on an annualized basis during the second quarter.
China&#8217;s annual inflation rate accelerated to 0.6% in August from 0.5% in the prior month, while producer prices fell by 1.8% year-over-year in August.
Economics
<ul>
<li>The Manheim Used Vehicle Value Index rose 1.2% month-over-month in August compared to a 2.8% gain in July.</li>
<li>U.S. wholesale inventories increased by 0.2% month-over-month to $903.5 billion in July compared to a preliminary reading of a 0.3% rise, and versus a revised flat reading a month ago.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/09/40771191/oracle-gears-up-for-q1-print-here-are-the-recent-forecast-changes-from-wall-streets-most-accurate-a">Oracle Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a></li>
</ul>

Eurozone

Commodities

Intraday Update

Markets

AMCX

CSWI

EGIO

Intelligent Bio Solutions Inc. - Common Stock

INBS

PEGY

RLAY

Nasdaq Surges Over 1%; US Wholesale Inventories Rise 0.2% In July

Telsey Advisory Group analyst Joseph Feldman maintains Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) with a Outperform and maintains $62 price target.

Telsey Advisory Group Maintains Outperform on Kroger, Maintains $62 Price Target

Healthcare Services Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCSG#NASDAQ">HCSG</a>) today announced the appointment of Vikas Singh as EVP &amp; Chief Financial Officer, effective September 3, 2024. He will oversee HCSG's accounting and finance operations, and play a key role in corporate development, investor relations, and the success of its long-term growth strategy.
Mr. Singh brings over two decades of diverse experience in finance, strategy and operations to the Company. Most recently, he served as Managing Director of Leveraged Finance &amp; Capital Markets at Bank of America Securities. Prior to that he worked in the Financial Sponsors Group at Credit Suisse and in the Asia-Pacific Credit Card Group at Citibank. Mr. Singh began his career with GSK's Consumer Healthcare Division and held roles in Sales Management and as National Brand Manager within the marketing organization.

Management

HCSG

HCSG Announces Appointment Of Vikas Singh As Chief Financial Officer, Effective September 3, 2024

Trupanion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>), the leading global provider of medical insurance for cats and dogs, announced today the official launch of its high-quality Trupanion product in Germany and Switzerland. The launch follows the Company's expansion to Continental Europe in 2022 with the acquisition of two rapidly growing pet insurance companies with strong expertise in the region. &nbsp;

Global

TRUP

Trupanion Announces The Official Launch Of Its High-Quality Trupanion Product In Germany And Switzerland

Telsey Advisory Group analyst Joseph Feldman maintains Holley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLLY#NYSE">HLLY</a>) with a Outperform and maintains $5.5 price target.

HLLY

Telsey Advisory Group Maintains Outperform on Holley, Maintains $5.5 Price Target

GameStop Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) investors and analysts will be hoping for more information about the company's financials and future growth initiatives when the company reports second-quarter financial results Tuesday<a href="https://www.benzinga.com/earnings"> after market close.</a>
Earnings Estimates: Analysts expect GameStop to report second-quarter revenue of $895.7 million according to data<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090924&amp;t=be2bearmibe3na1"> from Benzinga Pro.</a>
The company reported revenue of $1.16 billion in last year's second quarter, with analysts predicting a year-over-year decline.
GameStop has missed analyst estimates for revenue in three straight quarters and six of the last 10 quarters overall.
Analysts expect GameStop to report a loss of nine cents per share in the second quarter, which would be a decline from a loss of three cents per share in last year's second quarter.
GameStop has missed analyst estimates for earnings per share in two straight quarters and six of the last 10 quarters overall.
The video game retailer reported a loss of 12 cents in<a href="https://www.benzinga.com/news/earnings/24/06/39224137/gamestop-releases-q1-results-ahead-of-roaring-kitty-event-files-prospectus-to-raise-capital-via-equ"> the first quarter,</a> which ended a trend of profitability with the company reported earnings of 22 cents per share in the fourth quarter and break-even in the third quarter. 
The earnings report from GameStop comes with shares up 43% year-to-date, as seen on the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090924&amp;t=be2bearmibe3na1">Benzinga Pro chart</a> below, but after shares pulled back in recent months.
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent090924&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="1001" height="502" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09113906/Screenshot-169.png" alt="" class="wp-image-537843" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09113906/Screenshot-169.png 1001w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09113906/Screenshot-169-300x150.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/09113906/Screenshot-169-768x385.png 768w" sizes="(max-width: 1001px) 100vw, 1001px" /></a></figure>
Read Also:<a href="https://www.benzinga.com/general/gaming/24/08/40630875/gamestop-converts-stores-to-retro-retailers-to-help-gamers-find-old-nintendo-sega-game-boy-playsta"> GameStop Converts Stores To Retro Retailers To Help Gamers Find Old Nintendo, Sega, Game Boy, PlayStation, Xbox Consoles</a>
What Analysts Are Saying: GameStop receives minimal analyst coverage these days. In June, Wedbush analyst Michael Pachter<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39297523/gamestop-analyst-lowers-price-target-after-rambling-presentation-by-roaring-kitty-d"> lowered the price target </a>on shares from $13.50 to $11 along with an Underperform rating.
The lowered price target came with the company raising less money from share offerings than expected due to the timing of a presentation on YouTube by Roaring Kitty (aka Keith Gill).
"Given that GameStop's share price closed at $46 on June 6, we had assumed it would complete the sale at an average price of $40," Pachter said.
Key Items to Watch: GameStop has provided minimal updates and often releases earnings without conducting a conference call.
The second-quarter financial results could show strength in video game sales with the release of EA Sports "College Football 25," a highly anticipated game coming out in July that could be a bestseller.
GameStop could also provide an update on how it plans to use its cash from recent offerings. Investors have been anxiously awaiting the prospect of potential mergers and acquisitions by the video game company or investments thanks to a company rule change in 2023.
The earnings report comes shortly after the social media account of Roaring Kitty<a href="https://www.benzinga.com/news/24/09/40753645/roaring-kitty-posts-again-whats-going-on-with-gamestop-amc-chewy-stocks"> shared its first post </a>in months, with investors trying to decipher the clues that could potentially point to the investor selling their stake in Chewy and looking to GameStop once again.
 GME Price Action: GameStop stock traded up 2.76% at $24.58 on Monday at publication versus a 52-week trading range of $9.95 to $64.83.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40520253/gamestop-ceo-ryan-cohen-is-on-the-hunt-for-top-product-and-graphic-designers-what-you-should-know">GameStop CEO Ryan Cohen Is On The Hunt For Top Product And Graphic Designers — What You Should Know</a></li>
</ul>
Photo: rafapress via Shutterstock

Analyst Color

Earnings

Gaming

Previews

GameStop Q2 Earnings Preview: Analyst Estimates, Return To Profitability In Focus — Will Investors Get Update On Cash Plans?

Bank of America has reshuffled its sector outlooks, raising Utilities to &#8220;overweight&#8221; while downgrading <a href="https://www.benzinga.com/topic/energy">Energy to &#8220;market-weight.&#8221;</a>
The changes come as elevated volatility and policy uncertainty drive a recalibration of investment strategies. According to Savita Subramanian, Bank of America&#8217;s head of U.S. equity strategy, the shifting economic and political landscape has altered the risk-reward profiles <a href="https://www.benzinga.com/markets">of these key sectors.</a>
<h3 class="wp-block-heading">Utilities: Defensive Hedge With Growth Potential</h3>
Subramanian argues that Utilities, as tracked by the Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>), long regarded as a defensive sector, have become increasingly attractive in the <a href="https://www.benzinga.com/markets">current rate environment</a>.
As economic uncertainty persists, utilities offer stable fundamentals and a built-in defensive hedge against inflation. 
One of the core factors behind the Bank of America&#8217;s upgrade is their higher dividend yield, which has become more appealing given the revised outlook for interest rates.
Bank of America economists now predict terminal interest rates will reach 3.25% by 2025, lower than previous expectations, and this environment is favorable for income-generating assets like utilities. 
Further boosting the outlook for utilities is their exposure to artificial intelligence (AI) technologies. As companies in the sector begin to integrate AI for efficiency and operational improvements, there could be longer-term growth opportunities that hadn&#8217;t been factored in before, the analyst says.
Utilities are now benefiting from AI in ways that enhance productivity, making them not just a defensive play but also an indirect AI beneficiary, she adds.
<h3 class="wp-block-heading">Energy: From Value To Value Trap?</h3>
In contrast, Bank of America&#8217;s downgrade of the Energy sector, as tracked by the Energy&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>), comes amid concerns over political risk and weakening fundamentals. 
Although energy companies have improved in terms of quality and discipline compared to prior cycles, the sector faces rising uncertainty that could undermine its stability.
Subramanian warns that the supply discipline that has supported oil prices could start to unravel if the political environment changes. This coincides with Bank of America&#8217;s commodity strategists lowering their oil price forecasts, casting doubt on the sector&#8217;s growth prospects. 
&#8220;Energy stocks might look cheap, but they could be &#8216;cheap for a reason,'&#8221; she notes. 
One of the most worrying signals is the sector's earnings revisions: Energy now holds the &#8220;most negative earnings revision ratio of all sectors,&#8221; indicating that analysts are increasingly pessimistic about future earnings growth.
Moreover, Energy&#8217;s strong performance in recent years could turn into a liability if the political winds shift. Regulatory pressures, including potential changes in drilling policies and climate regulations, are key risks that could weigh heavily on the sector's outlook.
<h3 class="wp-block-heading">Avoiding The Tech Dip: Underweight Information Technology</h3>
Bank of America remains cautious on the beaten-down Information Technology sector, maintaining its &#8220;underweight&#8221; rating, despite arguments that the recent selloff has created a buying opportunity.
Subramanian highlights that Tech stocks still trade at record valuations, particularly in terms of enterprise value to sales (EV/Sales), making the sector vulnerable to further downside. 
&#8220;Technology is cyclical, not secular,&#8221; Subramanian asserts, meaning that its performance is closely tied to broader economic trends, not immune to them as some investors might hope.
Another concern is the upcoming changes in Standard &amp; Poor's index cap rules, which are likely to impact the largest Tech names. These changes could introduce concentration risk, leading to passive selling that could pressure some of the sector's mega-cap stocks. 
Read now:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/09/40773576/us-yield-curve-no-longer-inverted-why-this-time-the-recession-scenario-might-be-d">US Yield Curve No Longer Inverted: Why This Time The Recession Scenario Might Be Different For Investors</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Macro Economic Events

Sector ETFs

Upgrades

Downgrades

Econ #s

Economics

ETFs

Bank Of America Warns Energy Could Be 'Cheap For A Reason,' Highlights Utilities As Defensive Play

Axsome Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXSM#NASDAQ">AXSM</a>) underwent analysis by 17 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">10</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $129.06, along with a high estimate of $180.00 and a low estimate of $95.00. Observing a 0.41% increase, the current average has risen from the previous average price target of $128.53. 
<img src="https://www.benzinga.com/files/images/story/2024/1725897676_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Axsome Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$107.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$107.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Cerena Chen</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$140.00</td>
<td>-</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$180.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$105.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$180.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$106.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$107.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$131.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$130.00</td>
<td>-</td>
</tr>
<tr>
<td>Jason Gerberry</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$97.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Maintains</td>
<td>Buy</td>
<td>$106.00</td>
<td>$106.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Axsome Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Axsome Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Axsome Therapeutics's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Axsome Therapeutics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AXSM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Axsome Therapeutics analyst ratings.</a>
<h2>Get to Know Axsome Therapeutics Better</h2>
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
<h3>Axsome Therapeutics: A Financial Overview</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3 months period, Axsome Therapeutics showcased positive performance, achieving a revenue growth rate of 86.65% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -91.03%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Axsome Therapeutics's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -64.28%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Axsome Therapeutics's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -14.51%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Axsome Therapeutics's debt-to-equity ratio is below the industry average at 1.86, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AXSM

What Analysts Are Saying About Axsome Therapeutics Stock

Throughout the last three months, 6 analysts have evaluated EPR Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPR#NYSE">EPR</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $48.92, a high estimate of $54.00, and a low estimate of $45.00. Surpassing the previous average price target of $46.42, the current average has increased by 5.39%.
<img src="https://www.benzinga.com/files/images/story/2024/1725897662_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive EPR Props is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anthony Paolone</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$51.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>James Feldman</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$45.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>RJ Milligan</td>
<td>Raymond James</td>
<td>Maintains</td>
<td>Strong Buy</td>
<td>$54.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Ki Bin Kim</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$46.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$50.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Simon Yarmak</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$47.50</td>
<td>$42.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to EPR Props. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of EPR Props compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of EPR Props's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of EPR Props's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EPR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on EPR Props analyst ratings.</a>
<h2>Discovering EPR Props: A Closer Look</h2>
EPR Properties is a real estate investment trust that leases experiential properties in the United States and Canada. The company invests in two property segments: Experiential, including theaters, family entertainment centers, ski resorts, and other attractions; and Education, including early childhood education centers and private school properties. New investments are determined based on value and opportunity of the respective industry, location quality, and credit quality of tenants. The majority of revenue comes from the Experiential sector.
<h3>Financial Milestones: EPR Props's Journey</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Decline in Revenue: Over the 3 months period, EPR Props faced challenges, resulting in a decline of approximately -2.52% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Real Estate sector.
Net Margin: EPR Props's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 24.62%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.6%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): EPR Props's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.69% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.25.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Gain an Edge Using Pro's Market Moving News Breaks — 50% OFF

Gain an Edge Using Pro's Market Moving News Breaks — 50% OFF

Comments

Glomac

News

Latest news for Glomac (OTC:GLOCF) Stock